Ye Hua, Gao Ying, Guo Xiao-hui, Zhao Ming-hui
Department of Endocrinology, Peking University First Hospital, Beijing 100034, China.
Zhonghua Yi Xue Za Zhi. 2005 Dec 14;85(47):3323-7.
To analyze the clinical features and outcomes of hyperthyroidism patients positive in propylthiouracil (PTU)-induced antineutrophil cytoplasmic antibody (ANCA).
The clinical data, including the clinical manifestations, treatment, and outcomes of 45 PTU-induced ANCA positive patients with hyperthyroidism were prospectively studied.
Seventeen of the 45 patients had clinically evident vasculitis and 28 of the 45 patients were not complicated by vasculitis. In the vasculitis group, 13 patients (76.5%) had renal involvement manifested by hematuria, proteinuria, and renal insufficiency. 7 of them (41.2%) had lung involvement and 6 of them had hemoptysis. Perinuclear ANCA (p-ANCA) was detected in all 17 patients and 16 of them (94.1%) were anti-myeloperoxidase antibodies (MPO-ANCA) positive. PTU was discontinued in all 17 patients and the treatment was switched over to methimazole (MMI) in 6 patients. Four patients with severe organ involvement received prednisone and immunosuppressant for 6 to 12 months. No relapse or death occurred during the follow-up period (8 to 60 months with a median of 30 months). All the 17 patients achieved clinical remission except for two that developed end stage renal disease due to late diagnosis. 27 of the 28 patients without vasculitis (96.4%) were p-ANCA positive and 14 of them (50.0%) were MPO-ANCA positive. PTU treatment was discontinued in 24 patients and switched over to MMI treatment in 15 patients, and 4 patients continued to take low dose PTU. No vasculitis manifestation occurred during the follow-up period (3 to 36 months with a median of 20 months). However, the ANCA titer declined slowly in most patients in both groups.
PTU treatment should be discontinued without delay in the PTU-induced ANCA positive patients with hyperthyroidism. Treatment can be switched over to MMI when necessary. Patients with severe organ involvement should receive prednisone and immunosuppressant. No vasculitis relapse is found during the follow-up after withdrawal of PTU. However, ANCA may keep positive for a long time.
分析丙硫氧嘧啶(PTU)诱导的抗中性粒细胞胞浆抗体(ANCA)阳性的甲状腺功能亢进症患者的临床特征及转归。
前瞻性研究45例PTU诱导的ANCA阳性的甲状腺功能亢进症患者的临床资料,包括临床表现、治疗及转归。
45例患者中,17例有临床明显的血管炎,28例无血管炎并发症。血管炎组中,13例(76.5%)有肾脏受累,表现为血尿、蛋白尿和肾功能不全。其中7例(41.2%)有肺部受累,6例有咯血。17例患者均检测到核周型ANCA(p-ANCA),其中16例(94.1%)抗髓过氧化物酶抗体(MPO-ANCA)阳性。17例患者均停用PTU,6例换用甲巯咪唑(MMI)治疗。4例有严重器官受累的患者接受泼尼松和免疫抑制剂治疗6至12个月。随访期间(8至60个月,中位时间30个月)无复发或死亡。17例患者除2例因诊断延迟发展为终末期肾病外均达到临床缓解。28例无血管炎的患者中27例(96.4%)p-ANCA阳性,其中14例(50.0%)MPO-ANCA阳性。24例患者停用PTU治疗,15例换用MMI治疗,4例继续服用小剂量PTU。随访期间(3至36个月,中位时间20个月)无血管炎表现。然而,两组大多数患者的ANCA滴度下降缓慢。
PTU诱导的ANCA阳性的甲状腺功能亢进症患者应立即停用PTU治疗。必要时可换用MMI治疗。有严重器官受累的患者应接受泼尼松和免疫抑制剂治疗。停用PTU后随访期间未发现血管炎复发。然而,ANCA可能会长期保持阳性。